Here's What Key Metrics Tell Us About Viatris (VTRS) Q4 Earnings

Core Insights - Viatris reported revenue of $3.53 billion for the quarter ended December 2024, reflecting an 8.1% decline year-over-year and a surprise of -2.04% compared to the Zacks Consensus Estimate of$ 3.6 billion [1] - The company's EPS was $0.54, down from$ 0.61 in the same quarter last year, with an EPS surprise of -5.26% against the consensus estimate of $0.57 [1] Financial Performance - Total Net Sales were$ 3.52 billion, below the three-analyst average estimate of $3.59 billion, marking an 8.1% year-over-year decrease [4] - Other revenues reached$ 12.70 million, exceeding the estimated $11.47 million, representing an 11.4% increase year-over-year [4] - Net Sales in JANZ were$ 334.50 million, below the average estimate of $366.35 million, reflecting a 10.2% decline year-over-year [4] - Emerging Markets Net Sales were$ 513 million, slightly below the estimate of $538.93 million, with a year-over-year decrease of 17.1% [4] - Developed Markets- Brands Net Sales were$ 1.10 billion, compared to the $1.21 billion estimate, indicating a 16.3% year-over-year decline [4] - Net Sales in Greater China were$ 521.80 million, slightly below the estimate of $553.04 million, but showing a 1.3% year-over-year increase [4] - Developed Markets Net Sales totaled$ 2.15 billion, slightly below the estimate of $2.17 billion, with a 7.5% year-over-year decline [4] - Developed Markets- Generics Net Sales were$ 1.04 billion, below the estimate of $1.06 billion, reflecting a significant 27.1% year-over-year decrease [4] Stock Performance - Viatris shares have returned -16.6% over the past month, contrasting with the Zacks S&P 500 composite's -2.4% change [3] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [3]